Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Autoimmune (RA, IBD) Translational Studies
NHP Applications in Autoimmune (RA, IBD) Translational Studies, Securing Clinical Success Through Unrivaled Translational Fidelity! Are you currently facing high attrition rates in clinical trials for autoimmune therapies, difficulty in predicting human immunogenicity, and a lack of reliable efficacy models? We help you de-risk your drug candidate pipeline and accelerate IND submissions through proprietary, disease-specific NHPs and advanced immune-monitoring platforms.
We Provide High-Fidelity NHP Models for Autoimmune and Inflammatory Disease!
Translational failures stem from inadequate rodent models' species differences, leading to misleading efficacy and safety data. NHPs provide essential, high-fidelity data on human-like immune responses, joint pathology, and GI inflammation required for successful clinical translation.
Overview of NHP Applications
What Are Our Research Areas?
Preclinical research in chronic inflammatory and autoimmune diseases, such as Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD), demands models that accurately reflect human immune system complexity, genetic heterogeneity, and multi-organ pathology. Our services involve the utilization of nonhuman primate (NHP) models, which share over 90% genetic homology with humans, to study disease initiation, progression, and the pharmacodynamic effects of novel therapeutics. This is particularly crucial for biologics, cell, and gene therapies. We specialize in providing highly predictive data that bridges the gap between early discovery and successful clinical trials, providing crucial confidence for decisions.
Why Choose Us?
- Genetic and Immunological Similarity: NHPs possess an immune system structure, cell subset distribution, and cytokine profile that closely mirrors humans, essential for accurate immunogenicity and mechanism-of-action studies.
- Clinical Translational Relevance: Disease models (e.g., Collagen-Induced Arthritis, DSS-induced colitis) manifest pathology via clinical endpoints (e.g., CRP, colonoscopy) directly transferable to human clinical trial monitoring.
- Species-Specific Biologic Testing: NHPs are the only reliable model for accurately assessing the efficacy, PK, and safety of humanized monoclonal antibodies (mAbs) and other species-specific biologics.
Distributed under Unsplash License, from Unsplash.
Key Applications
Creative Biolabs' NHP models allow for highly specific and predictive testing across systemic and localized autoimmune conditions:
- Evaluating Disease-Modifying Anti-Rheumatic Drugs in RA: We utilize the established Rhesus Monkey Collagen-Induced Arthritis (CIA) model to quantify the reduction in joint swelling, assess systemic inflammation via biomarkers like C-Reactive Protein (CRP), and analyze the preservation of joint integrity via histopathology, providing critical efficacy data for biologics.
- Validating Novel GI Therapeutics for IBD: We employ the colitis NHP model to assess therapeutic efficacy using human clinical endpoints like the endoscopic colonoscopy score and fecal occult blood.
- Assessing Immunogenicity and Cytokine Storm Risk: We monitor the production of Anti-Drug Antibodies ADA and measure multiplex cytokine profiles across various tissues to predict human immunotoxicity and CRS risk, a mandatory assessment for novel cell and gene therapies.
- PK/PD of Biologics: Our studies determine the therapeutic half-life, tissue penetration, and receptor occupancy of mAbs and fusion proteins in a relevant physiological environment, which is critical for accurate human dose projection.
How Do Creative Biolabs Support Your Projects?
Our integrated service platform provides end-to-end support for your autoimmune and inflammatory therapeutic programs.
| Service Capability | Corresponding Application Area |
| Autoimmune Diseases Model Development | Efficacy testing of small molecules and biologics against RA, IBD, Systemic Lupus Erythematosus (SLE), and related conditions. |
| Antibody & Biologic Efficacy (Pharmacology & Efficacy) | Assessing target engagement and efficacy of complex biologics (e.g., bispecifics, ADCs) in systemic and localized inflammatory models. |
| Immunotoxicity & Cytokine Release Assays (CRAs) | In vitro and ex vivo prediction of immune-related adverse events using primary NHP cells, essential for advanced therapies. |
| ADA & Neutralizing Antibody (NAb) Assays | Quantifying the risk of anti-drug antibody formation and its impact on drug clearance and efficacy in NHPs. |
Translational Impact
Creative Biolabs' NHP models deliver unparalleled predictive power. Our translational data, such as real-time colonoscopy scores in IBD models and CRP kinetics in RA models, provide more reliable early proof of concept than any other preclinical system. This direct correlation to human clinical readouts leads to a significantly reduced risk of IND failure by providing regulators with high-fidelity safety and efficacy data from the most relevant bridge species to humans. We help clients ensure that their novel autoimmune drugs clear regulatory hurdles faster and more predictably.
Frequently Asked Questions
Q: How does your NHP model for Rheumatoid Arthritis compare in relevance to standard rodent models?
A: The NHP CIA model offers vastly superior translational relevance due to the genetic heterogeneity and immune complexity of the primates. Unlike inbred rodents, NHPs develop chronic arthritis pathology that better mimics human disease progression, including changes in CRP and joint degradation markers. This high-fidelity approach ensures the data you generate is significantly more predictive of clinical success.
Q: How do you handle the potential for immunogenicity when testing humanized biologics in NHPs?
A: Our Bioanalysis team implements a robust, tiered approach using NHP-specific reagents and highly sensitive platforms (MSD/ELISA). We monitor the kinetics of ADA formation throughout the study and concurrently measure neutralizing antibody (NAb) titers. This is critical for predicting potential loss of efficacy and safety concerns in human trials.
Q: For novel cell therapies, how can Creative Biolabs' NHP services help predict Cytokine Release Syndrome (CRS)?
A: We conduct ex vivo and in vivo immunotoxicity assessments utilizing freshly isolated NHP PBMCs. Our services include multi-color flow cytometry for immune cell phenotyping and multiplex cytokine/chemokine profiling. This allows us to predict the magnitude and kinetics of cytokine release, providing crucial safety margins for your clinical trial design.
Q: What is the typical turnaround time for an integrated PK/PD and efficacy study in a chronic NHP model?
A: Study timelines depend on the chronicity of the model, dosing regimen, and the complexity of the bioanalysis assays required. However, we streamline our processes, from animal conditioning to final report generation, to minimize lead time. Please reach out with your specific candidate molecule and protocol; our project management team will provide a detailed, optimized timeline within 48 hours.
Contact Us
Creative Biolabs delivers the predictive power required to successfully transition novel autoimmune and inflammatory therapeutics into the clinic. By utilizing NHP models for RA and IBD, we provide translational data that minimizes risk and maximizes your chances of IND approval and clinical success. To begin the conversation about integrating our high-fidelity NHP models into your preclinical strategy, please reach out to our expert team.